Migraine drug is first to tackle debilitating early symptoms

Fred Schwaller

Nature, 2025, vol. 641, issue 8064, 834-834

Abstract: Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent pre-headache fatigue and light sensitivity.

Keywords: Brain; Neuroscience (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-025-01503-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:641:y:2025:i:8064:d:10.1038_d41586-025-01503-3

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-025-01503-3

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().